HULL'S MAGIC BOX: BUILDING THE CASE FOR CLINICAL TRIALS USING ARGININE METHYLATION INHIBITORS AGAINST GBM

In brief

This study evaluates transcriptomic responses in glioblastoma tissue maintained on a microfluidics platform when treated with the arginine methylation inhibitor GSK3368715. The research aims to build evidence supporting clinical trial development for this novel therapeutic approach in GBM treatment.

Written by the GCMD Library team from the article.